-
CD20 monoantimmune Ublituximab was jointly treated with the PI3K inhibitor Umbralisib for chronic lymphocytic leukemia and was designated by the FDA Fast Track.
Time of Update: 2020-10-27
TG Therapeutics announced that the U.S. Food and Drug Administration (FDA) has awarded fast-track designations for the treatment of chronic lymphoblastic leukemia (CLL) in adults by combining its sugar-engineered anti-CD20 monoantilituximab with the oral dual inhibitors umbralisib of PI3K-δ and CK1-epsilon.
-
Nature: How is a bone marrow-boosting tumor hereditary?
Time of Update: 2020-10-27
researchers also used gene maps to identify HSC biological regulatory factors associated with MPN risk, and targeted mutation-to-functional determination showed that CHEK2 and GFI1B played a role in altering the function of HSCs to give disease risk.
-
Blood: BAX 335 gene therapy is expected to overcome type B haemophilia.
Time of Update: 2020-10-27
diagram of BAX 335 This report is primarily an interim analysis of safety, pharmacodynamics, effects on FIX activity, and immune response at 12 months.
8 adult male patients (20-69 years old, FIX activity range: 0.5%-2.0%) received the first dose of BAX 335 (IV, 3 times): 2.0×1011, 1.0×1012 or 3.0×1012 vector/kg genome.
-
Blood: Risk stratization therapy for infants with acute lymphoblastic leukemia.
Time of Update: 2020-10-27
studies have shown that risk stratification and early intensive chemotherapy can reduce low-risk KMT2A gene re-discharge in children for hematopoietic stem cell transplantation, and that the early clearance rate of micro-disease residues is also beneficial for patient prognosis.
-
Blood: Patients with Erdheim-Chester disease (ECD) have a higher risk of myeloma.
Time of Update: 2020-10-27
Erdheim-Chester disease (ECD) is a clone hematosis disease characterized by the accumulation of foam tissue cells in the organ, especially frequent injuries after the peritometrium, and brafV600E high-frequency mutations.
-
Blood: InO treats children with relapsed/refractic CD22-positive acute lymphoblastic leukemia.
Time of Update: 2020-10-27
, the journal Blood published the results of a Phase I clinical trial in children with the recommended Phase II dose (PR2D) of InO treatment for recurring/recurring (R/R)-CD22-positive acute lymphoblastic leukemia (ALL).
-
Blood: Tumor-targeted nanoparticles can improve the therapeutic effect of BCL2 and MCL1 double inhibition.
Time of Update: 2020-10-27
S63845 or Venetok encased in tumor-targeted nanoparticles can improve the therapeutic index of double inhibitory MCL1 and BCL2 proteins.
-
Dasatini-Bona spit monotherapy for adult ph-acute lymphoblastic leukemia.
Time of Update: 2020-10-27
Based on this, over the past 15 years, the GIMEMA (Gruppo Italiano Malattie Ematologiche dell'Adulto) team has adopted a chemotherapy-free induction program (applying glucoticoid pretreatment for 7 days), first by centrally evaluating all patients involved in the trial to determine the presence of BCR-ABL1 gene fusion, and then by inducing Ph-positive patients to use tyrosine kinase inhibitors (added corticosteroids).
-
J Thromb Haemost: Levels of coagulation factor in older adults are associated with a risk of venous thrombosis.
Time of Update: 2020-10-21
in this study of older adults, higher coagulation factors VIII, IX and XI were positively associated with VT risk, while the clotting enzyme principle was not.
-
Hyperphosphatemia drugs! Biomet's "Calcium Acetate Tablets" passed the consistency evaluation for the first time
Time of Update: 2020-10-21
acetate tablets are a phosphorus binding agent, mainly used to prevent and treat end-stage renal disease hyperphosphateemia.
end-stage kidney dialysis patients currently listed in China, high phosphorusemia treatment drugs are mainly Svilam, carbonate and calcium acetate.
-
Process: After the coronary artery is involved in the drug's escape stent. How long should double antiplatet treatment last?
Time of Update: 2020-10-21
Clinical prognosis This meta-analysis shows that compared with the 12-month DAPT program, the short-term DAPT combined P2Y12 inhibitor single treatment can reduce the risk of haemorrhage after the coronary artery intervention is placed into the drug escape stent, while the long-term DAPT treatment can reduce myocardial infarction, but there will be more bleeding events.
-
The top ten medical innovations of 2021 are out.
Time of Update: 2020-10-21
Hepatitis C universal treatment hepatitis C is a viral hepatitis C virus (HCV) infection, is one of the most common liver diseases, mainly through blood transfusions, needles, drug use and other transmission, according to the World Health Organization, the global HCV infection rate of about 3%, estimated that about 180 million people infected with HCV, about 35,000 new cases of hepatitis C each year.
-
Blood: The severity of the graft's resistance to host disease can be regulated by a type 2 cannabinin recipient.
Time of Update: 2020-10-20
above, these studies show that CB2R plays a key role in the regulation of GVHD and suggest that effective targeted treatment depends on the signal characteristics of the astration and the selectivity of the subject, as well as the composition of pathogenic immune effect cells.
-
Clin Cancer Res: Cell cycle protein D1 dependent transcription program predicts clinical prognosis in patients with heterocytic lymphoma.
Time of Update: 2020-10-20
the gene procedure in two MCL family exoded blood samples (n-53) and lymphatic tissue (n-106) to determine its biological and clinical relevance.
, the study found a cell cycle protein D1 (cyclin D1) dependent transcription procedure that was over-expressed in THECL and predicted clinical prognostication in patients.
-
China's golden decade of medical devices is coming, and upward growth change has come.
Time of Update: 2020-10-20
On October 12, 2020 Medical Device Industry Innovation and Development Conference was held in Shaoxing, which was co-sponsored by Shaoxing Municipal Government, Shaoxing Yuecheng Medical Device Indust
-
Blood: Induced mitigation of the effects of early MRD levels on low-intensity chemotherapy prognostics in all-in-one children.
Time of Update: 2020-10-20
patients selected based on the symptoms of induction therapy on the 19th day and the level of minimum residual disease (MRD) - lt;0.01% can obtain a better prognosis after low-intensity treatment.
-
Blood: RUNX1 and CBF beta-SMMHC jointly trans-activate abnormal myelin ancestral cells to promote leukemia.
Time of Update: 2020-10-20
above, this study shows that Runx1 is indispensable in the development of CBfb-MYH11-induced leukemia, and that it co-regulates key genes associated with the generation of functional AMP populations with CBF beta-SMMHC.
-
Science: For the first time, scientists are reconstructing HIV replication and integration in-body, with virus "protective shells" or therapeutic breakthroughs.
Time of Update: 2020-10-20
On October 9th researchers at the University of Virginia and the University of Utah published an article in Science entitled "Reconstitution and visualization of HIV-1 capsid-dependent complex and integration in vitro", which for the first time revealed the first step in HIV-infected host cells in vitro by building a cellless system - how the virus reverses and integrates in turn, and provides direct evidence that the viral shell is an important component of HIV infection.
-
Nat Biomed Eng: Accurately "fight" leukemia! Chinese scientists have developed a new vaccine for therapeutic leukemia.
Time of Update: 2020-10-20
, on October 12th researchers from the Institute of Process Engineering of the Chinese Academy of Sciences and the Pearl River Hospital of Southern Medical University developed a therapeutic vaccine that encapsulates antigen peptides and PD-1 antibodies in self-healing microcapsules to accurately treat leukemia.
-
Blood: The regulatory mechanism for protein reconstruction and cell removal in the final stage of red blood cell production.
Time of Update: 2020-10-19
together, these findings reveal a signaling path that is regulated by the formin during the eventual red blood cell generation process, linking the membrane skeleton to proteomic reconstruction, denuclearization, and cellular removal.
